QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Bodell, W. J. Articles by Levin, V. A. Search for Related Content PubMed PubMed Citation Social Bookmarking                   What's this?

Levels of N7-(2-hydroxyethyl)guanine as a molecular dosimeter of drug delivery to human brain tumors

Brain Tumor Research Center of the Department of Neurological Surgery, University of California, San Francisco, CA 94143-0555 (W.J.B., D.D.G.); Department of Neurosurgery (S.H.) and Department of Neuro-Oncology (V.A.L.), The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030

² Address correspondence and reprint requests to William J. Bodell, University of California, Box-0555, San Francisco, CA 94143-0555.

Abstract

The level of N7-(2-hydroxyethyl)guanine (N7-HOEtG), one of the DNA alkylation products formed by 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) treatment, was measured in human brain tumor samples by high performance liquid chromatography with electrochemical detection. The tumors from 6 recurrent chemotherapy-naïve patients with recurrent glioblastoma multiforme were analyzed as controls. The mean level of N7-HOEtG in DNA of these specimens was 0.42 pmol/mg DNA. Samples were also obtained from a patient with a recurrent glioblastoma multiforme after direct intratumoral therapy with BCNU in ethanol (DTI-015). The levels of N7-HOEtG in the samples distal, medial, and adjacent to the site of injection were 0.8, 2.6, and 369.5 pmol/mg DNA, respectively. Comparison of the level of N7-HOEtG detected in the distal sample after injection with BCNU in ethanol with the mean level of the untreated samples indicated that it was not sufficiently different to be ruled out as a chance occurrence. Comparison of the levels of N7-HOEtG in the medial and adjacent brain tumor samples with the mean level of the control samples showed values that were approximately 6- and 879-fold higher. These results demonstrate that intratumoral administration of BCNU in ethanol produces significant levels of DNA alkylation and suggest that DNA adduct measurements provide a unique molecular dosimeter to evaluate delivery of alkylating agents to brain tumors.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				W. J. Bodell, A. P. Bodell, and D. D. Giannini Levels and distribution of BCNU in GBM tumors following intratumoral injection of DTI-015 (BCNU-ethanol) Neuro-oncol, January 1, 2007; 9(1): 12 - 19. [Abstract] [Full Text] [PDF]

				D. E. Hall, B. A. Moffat, J. Stojanovska, T. D. Johnson, Z. Li, D. A. Hamstra, A. Rehemtulla, T. L. Chenevert, J. Carter, D. Pietronigro, et al. Therapeutic Efficacy of DTI-015 using Diffusion Magnetic Resonance Imaging as an Early Surrogate Marker Clin. Cancer Res., December 1, 2004; 10(23): 7852 - 7859. [Abstract] [Full Text] [PDF]